ProfileGDS5678 / 1438431_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 72% 72% 70% 76% 72% 68% 79% 84% 83% 71% 74% 75% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.9288675
GSM967853U87-EV human glioblastoma xenograft - Control 24.5570672
GSM967854U87-EV human glioblastoma xenograft - Control 34.6448372
GSM967855U87-EV human glioblastoma xenograft - Control 44.4795370
GSM967856U87-EV human glioblastoma xenograft - Control 55.09676
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5639272
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.2264768
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.5070579
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.1994284
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0497383
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4752171
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8728474
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.9082375
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.8237174